Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer
A Phase I Trial of Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer (CRPC)
Sponsor: Bayer
This PHASE1 trial investigates Metastatic Castrate Resistant Prostate Cancer and is currently completed. Bayer leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Nov 2025 — Present [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
May 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1
-
Sep 2024 — May 2025 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
-
Apr 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 7 earlier versions
-
Apr 2023 — Apr 2024 [monthly]
Recruiting PHASE1
-
Mar 2022 — Apr 2023 [monthly]
Recruiting PHASE1
-
Mar 2021 — Mar 2022 [monthly]
Recruiting PHASE1
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE1
-
Sep 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
Jun 2019 — Sep 2020 [monthly]
Recruiting PHASE1
-
Dec 2018 — Jun 2019 [monthly]
Recruiting PHASE1
First recorded
Jan 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Henry Ford Hospital
- Lahey Clinic
- Ohio State University Comprehensive Cancer Center
- Tufts Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .